AstraZeneca/Ardea Biosciences

Target: Ardea Biosciences
Buyer: AstraZeneca ($AZN)
Price: $1.3 billion
Closed: June 20, 2012

One of the last things CEO David Brennan did before being shown the door was fork over $1.3 billion so AstraZeneca could get its hands on Ardea's promising gout treatment candidate. In some ways, it seemed a deal born of desperation.

Brennan was under pressure to do something about its pipeline after a series of setbacks, like the implosion of its depression drug program it had partnered on with Targacept ($TRGT). With the Ardea deal, AstraZeneca ventured into a field completely outside the realm of its expertise. The question now is whether new CEO Pascal Soriot sees value in pursuing the program.

AstraZeneca/Ardea Biosciences
Read more on

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.